Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations - PubMed (original) (raw)
. 1999 Jul 1;94(1):225-32.
Affiliations
- PMID: 10381517
Free article
Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations
T Fioretos et al. Blood. 1999.
Free article
Abstract
An isochromosome of the long arm of chromosome 17, i(17q), is the most frequent genetic abnormality observed during the disease progression of Philadelphia chromosome-positive chronic myeloid leukemia (CML), and has been described as the sole anomaly in various other hematologic malignancies. The i(17q) hence plays a presumably important pathogenetic role both in leukemia development and progression. This notwithstanding, the molecular consequences of this abnormality have not been investigated in detail. We have analyzed 21 hematologic malignancies (8 CML in blast crisis, 8 myelodysplastic syndromes [MDS], 2 acute myeloid leukemias, 2 chronic lymphocytic leukemias, and 1 acute lymphoblastic leukemia) with i(17q) by fluorescence in situ hybridization (FISH). Using a yeast artificial chromosome (YAC) contig, derived from the short arm of chromosome 17, all cases were shown to have a breakpoint in 17p. In 12 cases, the breaks occurred within the Smith-Magenis Syndrome (SMS) common deletion region in 17p11, a gene-rich region which is genetically unstable. In 10 of these 12 cases, we were able to further map the breakpoints to specific markers localized within a single YAC clone. Six other cases showed breakpoints located proximally to the SMS common deletion region, but still within 17p11, and yet another case had a breakpoint distal to this region. Furthermore, using chromosome 17 centromere-specific probes, it could be shown that the majority of the i(17q) chromosomes (11 of 15 investigated cases) were dicentric, ie, they contained two centromeres, strongly suggesting that i(17q) is formed through an intrachromosomal recombination event, and also implicating that the i(17q), in a formal sense, should be designated idic(17)(p11). Because i(17q) formation results in loss of 17p material, potentially uncovering the effect of a tumor suppressor on the remaining 17p, the occurrence of TP53 mutations was studied in 17 cases by sequencing the entire coding region. In 16 cases, no TP53 mutations were found, whereas one MDS displayed a homozygous deletion of TP53. Thus, our data suggest that there is no association between i(17q) and coding TP53 mutations, and that another tumor suppressor gene(s), located in proximity of the SMS common deletion region, or in a more distal location, is of pathogenetic importance in i(17q)-associated leukemia.
Similar articles
- Mapping of the breakpoints on the short arm of chromosome 17 in neoplasms with an i(17q).
Scheurlen WG, Schwabe GC, Seranski P, Joos S, Harbott J, Metzke S, Döhner H, Poustka A, Wilgenbus K, Haas OA. Scheurlen WG, et al. Genes Chromosomes Cancer. 1999 Jul;25(3):230-40. doi: 10.1002/(sici)1098-2264(199907)25:3<230::aid-gcc5>3.0.co;2-e. Genes Chromosomes Cancer. 1999. PMID: 10379869 - Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p.
Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K. Nakai H, et al. Cancer Res. 1992 Dec 1;52(23):6588-93. Cancer Res. 1992. PMID: 1423304 - Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature.
Hernández-Boluda JC, Cervantes F, Costa D, Carrió A, Montserrat E. Hernández-Boluda JC, et al. Leuk Lymphoma. 2000 Jun;38(1-2):83-90. doi: 10.3109/10428190009060321. Leuk Lymphoma. 2000. PMID: 10811450 - Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
Johansson B, Fioretos T, Mitelman F. Johansson B, et al. Acta Haematol. 2002;107(2):76-94. doi: 10.1159/000046636. Acta Haematol. 2002. PMID: 11919388 Review. - [Cytogenetic and clinical features of Philadelphia chromosome positive leukemias].
Becher R, Kloke O. Becher R, et al. Verh Dtsch Ges Pathol. 1990;74:36-42. Verh Dtsch Ges Pathol. 1990. PMID: 1708614 Review. German.
Cited by
- Molecular genetic characterization of myeloid neoplasms with idic(X)(q13) and i(X)(q10).
Brunetti M, Andersen K, Trøen G, Micci F, Spetalen S, Lenartova A, Tandsæther MR, Panagopoulos I. Brunetti M, et al. Front Oncol. 2024 Sep 26;14:1428984. doi: 10.3389/fonc.2024.1428984. eCollection 2024. Front Oncol. 2024. PMID: 39391249 Free PMC article. - Donor Cell Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: A Case Report and Literature Review.
Micheloni G, Frattini A, Donini M, Dusi S, Leszl A, Di Meglio A, Pigazzi M, Musio A, Zecca M, Mina T, Rabusin M, Roccia P, Bernasconi P, Dambruoso I, Minelli A, Montalbano G, Acquati F, Porta G, Valli R, Pasquali F. Micheloni G, et al. Genes (Basel). 2023 Nov 16;14(11):2085. doi: 10.3390/genes14112085. Genes (Basel). 2023. PMID: 38003028 Free PMC article. Review. - Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate.
Siti Mariam I, Norhidayah R, Zulaikha AB, Nazihah MY, Rosline H, Kausar GA, Sarina S, Azlan H, Ankathil R. Siti Mariam I, et al. Front Oncol. 2022 Aug 8;12:720845. doi: 10.3389/fonc.2022.720845. eCollection 2022. Front Oncol. 2022. PMID: 36003793 Free PMC article. - Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A, Kasprzak A, Germing U. Kuendgen A, et al. Front Oncol. 2021 Nov 16;11:778741. doi: 10.3389/fonc.2021.778741. eCollection 2021. Front Oncol. 2021. PMID: 34869027 Free PMC article. Review. - Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.
Ochi Y, Yoshida K, Huang YJ, Kuo MC, Nannya Y, Sasaki K, Mitani K, Hosoya N, Hiramoto N, Ishikawa T, Branford S, Shanmuganathan N, Ohyashiki K, Takahashi N, Takaku T, Tsuchiya S, Kanemura N, Nakamura N, Ueda Y, Yoshihara S, Bera R, Shiozawa Y, Zhao L, Takeda J, Watatani Y, Okuda R, Makishima H, Shiraishi Y, Chiba K, Tanaka H, Sanada M, Takaori-Kondo A, Miyano S, Ogawa S, Shih LY. Ochi Y, et al. Nat Commun. 2021 May 14;12(1):2833. doi: 10.1038/s41467-021-23097-w. Nat Commun. 2021. PMID: 33990592 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous